Participants will receive eltrombopag in the form of a 75 mg film-coated tablet, which is a pill covered in a thin layer to make it easier to swallow. The study is conducted under fasting conditions, meaning no food is consumed for a certain period before taking the medication. The process involves a crossover design, where individuals receive both the test version and the comparator version of the medication at different times during the study period.

The purpose of this study is to find out if romiplostim can help maintain platelet counts high enough to allow patients to receive their full chemotherapy doses on time without delays or reductions. The study will compare romiplostim with placebo to measure its effectiveness. Participants entering the study must have a platelet count at or below a certain level and must have at least three more cycles of chemotherapy planned. The chemotherapy cycles are given every 21 or 28 days depending on the specific treatment plan.

During the study, participants will receive either romiplostim or placebo as an injection under the skin while continuing their regular chemotherapy treatment. The study medication will be given for a treatment period lasting up to 12 weeks. Doctors will monitor platelet counts, track whether chemotherapy doses need to be changed due to low platelets, and watch for any bleeding problems or other side effects. Participants will continue to be followed for safety monitoring for up to 36 months to check for any long-term effects.

The research involves two parts. The first part focuses on pharmacokinetics, which is the study of how a drug moves through the body. The second part focuses on how well the treatment works to increase the blood cell count. During the study, the amount of the drug in the blood and the ability to complete cycles of cancer treatment without needing to change the doses of other medications will be observed.

The purpose of this study is to compare two different versions of Eltrombopag tablets to see if they work in the same way in the body when taken with food. This is called a bioequivalence study, which means researchers want to confirm that both versions of the medicine are absorbed into the bloodstream at similar rates and amounts. The study will involve healthy volunteers rather than patients with the conditions mentioned, as this is a standard approach for testing whether different versions of a medication behave similarly in the body.

Participants will receive a single dose of each version of the medication on two separate occasions, with a break between doses. They will take the medication after eating a meal, as the study examines how the medicine works under fed conditions. During the study, blood samples will be collected at various times to measure the amount of medication in the bloodstream. The safety of the medication will also be monitored by checking for any unwanted effects, performing heart tracings, measuring vital signs like blood pressure and heart rate, and conducting laboratory tests on blood samples.

The purpose of this study is to find out if romiplostim given before heart surgery can help reduce the severity of low platelet counts after the surgery compared to placebo. Patients will receive their first injection between 14 and 10 days before their scheduled heart surgery. The study will look at the lowest platelet count that occurs from the end of the heart surgery until seven days after the surgery. The study will also track other factors such as how much bleeding occurs after surgery, whether patients need transfusions of platelets or other blood products, and how patients recover after their operation.

Throughout the study, doctors will monitor platelet counts and other blood measurements at different time points before and after surgery. They will also track any complications that may occur, such as bleeding events, blood clots in veins or arteries, infections, and how long patients need to stay in the intensive care unit and in the hospital. The study will follow patients for up to three months after surgery to assess their overall recovery and any side effects from the treatment. The treatment period with the study medication lasts for 14 days, and patients will receive up to three injections during this time.

The purpose of the study is to evaluate how effective and safe KIg10 is for adults with chronic ITP. Participants in the study will receive the treatment and have their platelet levels monitored to see if there is an increase, which is a sign of improvement. The study will also check for any side effects or bleeding episodes during the treatment period.

Participants will be involved in the study for a period of time, during which they will receive the treatment and have regular check-ups to monitor their health and response to the treatment. The study aims to gather information on how quickly and effectively the treatment works, how long the effects last, and any changes in bleeding symptoms. This information will help determine the potential benefits of KIg10 for people with chronic ITP.

The purpose of the study is to evaluate how well selinexor works on its own in treating myelofibrosis. Participants in the study will take selinexor orally for a period of up to 105 days. During this time, they will have regular check-ups to monitor their health and see how the treatment is affecting their condition. The study will also compare the effects of selinexor with those of a placebo, which is a substance with no active medication, to better understand its effectiveness.

Throughout the study, participants will undergo various assessments, including imaging tests like MRI or CT scans, to measure changes in their spleen size and other health indicators. The study aims to gather information on the overall response to the treatment, including any changes in symptoms and side effects. This research will help determine if selinexor is a beneficial treatment option for people with myelofibrosis who have not been treated with JAK inhibitors before.